Group 1: Clinical Progress and Product Development - The long-acting growth hormone clinical trial is progressing smoothly, with completion expected in 2017 [1] - The new product, follicle-stimulating hormone, is being positioned in the market and is anticipated to perform well due to its mature product status and advanced recombinant technology [2] - The sales of growth hormone powder and water injections are expected to continue growing [2] Group 2: Financial Performance and Market Strategy - Huakang Pharmaceutical experienced negative revenue growth in the first three quarters due to multiple factors including public hospital bidding price reductions and rising production costs [3] - Huakang Pharmaceutical is refining its sales strategy to expand market coverage, aiming for a certain degree of growth in performance next year as market adjustments take place [3]

Financial Performance - The company achieved a revenue of 1.07 billion CNY in the first half of the year, representing a year-on-year growth of 22.62% [3] - The net profit attributable to shareholders was 170 million CNY, with a year-on-year increase of 62.27% [3] - The pharmaceutical segment generated 860 million CNY in revenue, growing by 4.99%, and net profit of 150 million CNY, up by 16.39% [3] Product Development and Market Strategy - JinSai Pharmaceutical's net profit reached 180 million CNY, marking a 15.11% increase [3] - The GMP certification for follicle-stimulating hormone has been announced, allowing for official production and sales [4] - The company is exploring a marketing model through the establishment of Shanghai Tongxin Hospital Management Company to enhance competitive positioning [4][5] Market Trends and Challenges - The pharmaceutical industry is facing challenges due to mandatory price reductions and regulatory constraints from public hospital procurement [3] - The sales growth of the pharmaceutical segment is showing signs of slowing down due to external and internal factors [3] Future Outlook and Innovations - The company is focusing on the development of thymosin α1 and other potential products, with a strong emphasis on growth hormone sales [6] - Plans for mergers and acquisitions are centered on the health industry, with a focus on innovative development and market expansion [7][8] - The long-acting growth hormone is expected to gain market acceptance as it progresses through clinical phases [8]

Group 1: Company Control and Management - The change of the actual controller to Changchun Longxiang Group will not impact the company's development strategy or daily operations [3] - The local state-owned enterprise reform implementation measures have not yet been released, awaiting guidance from relevant authorities [3] - The increase in stock holdings by directors, supervisors, and executives is a voluntary action based on confidence in the company's future, not a regulatory requirement [4] Group 2: Market and Product Development - The market sales of long-acting growth hormone are progressing as planned, with sales performance meeting expectations [6] - The production of follicle-stimulating hormone is being organized, with sales expected to commence as products are sold through public hospital tenders [6] - The clinical trial for the nasal spray flu vaccine is expected to take about one year, with the launch date dependent on regulatory review [7] Group 3: Investment and Partnerships - The establishment of Shanghai Tongxin Hospital Management Co., Ltd. is underway, with registration and acquisition research progressing as planned [5] - The project for the heart stent by Xi'an Aide Wansi is currently in preclinical research, showing optimistic progress [7] - The self-inspection report for the Aisena peptide project has been submitted, currently awaiting review by the regulatory department [7]

长春高新技术产业（集团）股份有限公司 2021 年年度报告全文 证券代码：000661 证券简称：长春高新 公告编号：2022-011 长春高新技术产业（集团）股份有限公司 2021 年年度报告 2022 年 03 月 1 长春高新技术产业（集团）股份有限公司 2021 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人马骥、主管会计工作负责人朱兴功及会计机构负责人(会计主管 人员)陈彤声明：保证本年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本年度报告中涉及未来计划、发展战略等前瞻性陈述，不构成公司对投资 者的实质承诺，敬请广大投资者注意投资风险。 公司已在董事会报告中对公司未来发展可能面对的风险因素及对策进行了 详细阐述，同时经营计划、经营目标并不代表公司对 2022 年度的盈利预测，能 否实现取决于市场状况变化等多种因素。 公司经本次董事会审议通过的利润分配预案为：以目前总股本 404,720,290 股扣除回 ...